MCM
BPMC

Makena Capital Management’s Blueprint Medicines BPMC Stock Holding History

Makena Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-38,924
Closed -$4.37M – 46
2020
Q4 		$4.37M Hold
38,924
– – 2.42% 17
2020
Q3 		$3.61M Hold
38,924
– – 2.12% 22
2020
Q2 		$3.04M Hold
38,924
– – 1.85% 29
2020
Q1 		$2.28M Hold
38,924
– – 2.2% 24
2019
Q4 		$3.12M Buy
+38,924
New +$2.91M 2.75% 19

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Makena Capital Management's BPMC Position: Q1 2021 in Review

Makena Capital Management sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 38,924 shares — an estimated $4.37M sold.

Makena Capital Management first reported a position in BPMC in Q4 2019 and held it in 5 quarters. The position peaked at $4.37M in Q4 2020. 264 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

  • Makena Capital Management reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
  • Makena Capital Management sold 38,924 Blueprint Medicines shares in Q1 2021, an estimated $4.37M.
  • Makena Capital Management first reported a position in Blueprint Medicines in Q4 2019 and held it in 5 quarters.
  • Makena Capital Management's Blueprint Medicines position peaked at $4.37M in Q4 2020.
  • 264 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Makena Capital Management's 13F filing for Q1 2021, filed 12 May 2021.